GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atrys Health SA (XMAD:ATRY) » Definitions » Debt-to-EBITDA

Atrys Health (XMAD:ATRY) Debt-to-EBITDA : 12.44 (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Atrys Health Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Atrys Health's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €71.6 Mil. Atrys Health's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €189.7 Mil. Atrys Health's annualized EBITDA for the quarter that ended in Dec. 2023 was €21.0 Mil. Atrys Health's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 12.44.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Atrys Health's Debt-to-EBITDA or its related term are showing as below:

XMAD:ATRY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.36   Med: 10.3   Max: 93.18
Current: 9

During the past 8 years, the highest Debt-to-EBITDA Ratio of Atrys Health was 93.18. The lowest was 1.36. And the median was 10.30.

XMAD:ATRY's Debt-to-EBITDA is ranked worse than
88.32% of 274 companies
in the Biotechnology industry
Industry Median: 1.31 vs XMAD:ATRY: 9.00

Atrys Health Debt-to-EBITDA Historical Data

The historical data trend for Atrys Health's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atrys Health Debt-to-EBITDA Chart

Atrys Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial 11.28 24.67 93.18 18.87 9.00

Atrys Health Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.97 8.33 -162.12 6.98 12.44

Competitive Comparison of Atrys Health's Debt-to-EBITDA

For the Biotechnology subindustry, Atrys Health's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atrys Health's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atrys Health's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Atrys Health's Debt-to-EBITDA falls into.



Atrys Health Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Atrys Health's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(71.613 + 189.689) / 29.024
=9.00

Atrys Health's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(71.613 + 189.689) / 21.004
=12.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


Atrys Health  (XMAD:ATRY) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Atrys Health Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Atrys Health's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Atrys Health (XMAD:ATRY) Business Description

Traded in Other Exchanges
Address
c/ Provença, 392 planta baja, Barcelona, ESP, 08025
Atrys Health SA is a Spain based biomedical company which focuses on developing tools for the diagnosis and treatment of cancer and precancerous conditions. It offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics. The company uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology.

Atrys Health (XMAD:ATRY) Headlines

No Headlines